Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique,
non-viral proprietary platform designed to deliver tumor suppressor genes to
cancer cells, today announced its February 4, 2020 receipt of notice from The
Nasdaq Stock Market LLC (“Nasdaq”) indicating that the company has regained
compliance with the minimum bid price requirement under Nasdaq Listing Rule
5550(a)(2) (the “Bid Price Rule”) for continued listing on The Nasdaq Capital
Market. Accordingly, the company has regained compliance with the Bid Price
Rule and Nasdaq considers the matter closed.
To view the full press release, visit http://ibn.fm/MZIf4
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company developing
potentially life-changing technologies for cancer patients based upon a unique
proprietary technology platform. Genprex’s platform technologies are designed
to administer cancer-fighting genes by encapsulating them into nanoscale hollow
spheres called nanovesicles, which are then administered intravenously and
taken up by tumor cells where they express proteins that are missing or found
in low quantities. The company’s lead product candidate, Oncoprex(TM)
immunogene therapy for non-small cell lung cancer (“NSCLC”), has a multimodal
mechanism of action whereby it has been shown to interrupt cell signaling
pathways that cause replication and proliferation of cancer cells, re-establish
pathways for apoptosis, or programmed cell death, in cancer cells, and modulate
the immune response against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. In January 2020, the FDA granted Fast
Track Designation for Oncoprex(TM) immunogene therapy for NSCLC in combination
therapy with osimertinib (AstraZeneca’s Tagrisso(R)). For more information,
please visit the company’s web site at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
